SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Harvard Bioscience Inc – ‘8-K’ for 5/8/17 – ‘EX-16.1’

On:  Thursday, 5/11/17, at 4:01pm ET   ·   For:  5/8/17   ·   Accession #:  1171843-17-2987   ·   File #:  1-33957

Previous ‘8-K’:  ‘8-K’ on / for 4/27/17   ·   Next:  ‘8-K’ on 5/19/17 for 5/18/17   ·   Latest:  ‘8-K’ on 4/3/24 for 3/28/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 5/11/17  Harvard Bioscience Inc            8-K:4,9     5/08/17    2:33K                                    Globenewswire Inc./FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     16K 
 2: EX-16.1     Letter re: Change in Certifying Accountant          HTML      7K 


EX-16.1   —   Letter re: Change in Certifying Accountant


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



Exhibit 16.1

 

 

 
KPMG LLP
One Broadway, 15th Floor
Cambridge, MA 02142
Telephone     +1 617 475 4700
Fax                +1 617 475 4799
kpmg.com

 

 

 

 

 

May 9, 2017

 

Securities and Exchange Commission
Washington, D.C. 20549

 

Ladies and Gentlemen:

 

We were previously principal accountants for Harvard Bioscience, Inc. (the “Company”) and, under the date of March 16, 2017, we reported on the consolidated financial statements of Harvard Bioscience, Inc. as of December 31, 2016 and 2015 and for each of the years ended December 31, 2016, 2015 and 2014 and the effectiveness of internal control over financial reporting as of December 31, 2016. On May 8, 2017, we were dismissed. We have read Harvard Bioscience, Inc.’s statements included under Item 4.01 of its Form 8-K dated May 8, 2017, and we agree with such statements except that we are not in a position to agree or disagree with Harvard Bioscience, Inc.’s statements that: 1) Grant Thornton LLP was not consulted regarding the application of accounting principles to a specified transaction or the type of audit opinion that might be rendered on Harvard Bioscience, Inc.’s consolidated financial statements, or the effectiveness of internal control over financial reporting; 2) a competitive process was conducted by the audit committee of the board of directors to determine the independent registered public accountants; 3) the change was approved by the audit committee of the board of directors; and 4) management is committed to remediating the Company’s material weaknesses in a timely fashion.

 

Very truly yours,

 

 

/s/ KPMG LLP

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  KPMG LLP is a Delaware limited liability partnership and the U.S. member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative (“KPMG International”), a Swiss entity.  


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on:5/11/17
5/9/17
For Period End:5/8/1710-Q
3/16/1710-K
12/31/1610-K,  NT 10-K
12/31/1510-K,  4,  NT 10-K,  SD
12/31/1410-K,  10-K/A,  4,  4/A,  SD
 List all Filings 
Top
Filing Submission 0001171843-17-002987   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 10:04:05.1am ET